Abstract
Abstract[123I]1‐[2‐(Diphenylmethoxy)ethyl]‐4‐[3‐(m‐iodophenyl)‐2‐propenyl]piperazine ([123I]2), a potential SPECT imaging agent for dopamine reuptake sites was efficiently synthesized in 4 steps from 1‐[2‐(diphenylmethoxy)ethyl]piperazine (3). A key step in the synthesis was the selective AIH3‐mediated reduction of 1[2‐(diphenylmethoxy)ethyl‐4‐(m‐bromocinnamoyl] piperazine (4) to 1‐[2‐(diphenylmethoxy)ethyl‐4‐(3‐(m‐bromophenyl)‐2‐propenyl]piperazine(5). The 123I label of [123I]2 was introduced in the final step in up to 90% radiochemical yield by treatment of the organotin precursor 1‐(2‐(diphenylmethoxy)ethyl‐4‐[3‐[(m‐(tributyl stannyl)phenyl]‐2‐propenyl]piperazine (6) with Na123I in aqueous CH3CO3H.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
